Abstract

Background: Quality of life assessment in patients with Multiple sclerosis (MS) is invaluable for a proper evaluation of disease severity, appropriate choice of therapy and monitoring of its effects. The aim of this study was to assess the quality of life of patients with MS and to identify gender differences in examined outcome. Patients and Methods: A descriptive cross-sectional study was conducted from August 2010 to May 2011. The data were obtained by anonymous survey of 110 patients. Quality of life of the patients was measured by the instrument 'The World Health Organization Quality of Life (WHOQOL) - BREF'. Data on gender and age of patients, type of MS, the number of relapses during the last 2 years, current therapy, dose regimens of certain drugs, and the amount of money the patients spend each month for the purchase of drugs that are not issued at the expense of health insurance fund, were obtained using a distinct structured questionnaire. The collected data were analyzed using simple descriptive statistics and Student's t-test for independent samples. Results: Of the total 110 interviewed patients, 70% (n = 77) were female and 30% (n = 33) male. There were no significant gender differences in the disease duration, number of relapses in the last two years and spending of more than 1000 RSD per month for purchase of drugs that were not issued at the expense of the health insurance fund. Significantly better quality of life was recorded in women than men (p = 0.031), mainly on account of differences in the assessment of the domain of 'Environment' (p = 0.025), as measured by WHOQOL-BREF scale. Conclusion: This study has shown that females tolerate difficulties caused by multiple sclerosis better than men, and also have a better quality of life than men with the same clinical form of the disease and identical symptoms, treated with the same therapy.

Highlights

  • Quality of life assessment in patients with Multiple sclerosis (MS) is invaluable for a proper evaluation of disease severity, appropriate choice of therapy and monitoring of its effects

  • Quality of life of the patients was measured by the instrument "The World Health Organization Quality of Life (WHOQOL) - BREF"

  • There were no significant gender differences in the disease duration, number of relapses in the last two years and spending of more than 1000 RSD per month for purchase of drugs that were not issued at the expense of the health insurance fund

Read more

Summary

Objectives

The aim of this study was to assess the quality of life of patients with MS and to identify gender differences in examined outcome

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call